Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitorAcquisition further ...
9d
New Biomarker Discovered For Cognitive Symptoms Of Schizophrenia, Could Serve As Drug Target: Study
A study has found a new biomarker of schizophrenia, which could also serve as a drug target for treating cognitive symptoms ...
Schizophrenia remains one of the most misunderstood and stigmatized conditions. In the U.S. alone, an estimated 2.8 million ...
Researchers identified a protein biomarker linked to schizophrenia and developed a synthetic peptide that restores neural ...
Stress experienced during adolescence causes deeper and more lasting changes in the brain than the same stress experienced in ...
LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive ...
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop ...
Current schizophrenia medications treat symptoms such as hallucinations and delusions, but do little for cognitive symptoms ...
Anxiety, depression and post-traumatic stress disorder (PTSD) are among the most common mental health conditions for which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results